BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
US Army
Daiichi Sankyo
Federal Trade Commission

Generated: November 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 3,998,790

« Back to Dashboard

Summary for Patent: 3,998,790

Title: Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
Abstract:Para-substituted phenoxy-hydroxypropylamines having the general formula ##STR1## and pharmaceutically acceptable, non-toxic acid addition salts thereof, wherein R' is an isopropyl or tertiarybutyl radical; Z is a member selected from the group consisting of -OR", -SR", and -NHCOOR", R" being a straight or branched lower alkyl radical having 1 to 3 carbon atoms; and n is 1, 2, or 3, are disclosed as are methods for their preparation. Pharmaceutical preparations are prepared whose active ingredients include at least one of the newly discovered phenoxy-hydroxypropylamine compounds. Therapeutically effective doses of these preparations selectively block the .beta.-receptors of the heart making them useful in treating heart diseases in animals including humans.
Inventor(s): Brandstrom; Arne Elof (Goteborg, SW), Carlsson; Per Arvid Emil (Goteborg, SW), Carlsson; Stig Ake Ingemar (Molnlycke, SW), Corrodi; Hans Rudolf (Sodertalje, SW), Ek; Lars (Onsala, SW), Ablad; Bengt Arne Hjalmar (Goteborg, SW)
Assignee: Aktiebolaget Hassle (Goteborg, SW)
Application Number:05/433,451
Patent Claim Types:
see list of patent claims

No matches for this query

International Patent Family for Patent: 3,998,790

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria134971► Subscribe
Austria307386► Subscribe
Austria310144► Subscribe
Austria317181► Subscribe
Belgium762629► Subscribe
Canada982140► Subscribe
Switzerland563338► Subscribe
Switzerland563339► Subscribe
Switzerland563340► Subscribe
Switzerland572895► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Johnson and Johnson
Harvard Business School
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus